Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 21 peer-reviewed journal articles Updated
Medical oncology · Estrogen Receptor-Positive Breast Cancer

Systemic Therapy: Endocrine & Targeted Treatments

At a Glance

For ER-positive, HER2-negative breast cancer, endocrine therapy is the foundation of systemic treatment: tamoxifen blocks estrogen signaling, while aromatase inhibitors lower estrogen. Ovarian suppression or a CDK4/6 inhibitor may be added for selected patients.

While surgery and radiation address the cancer in the breast, systemic therapy—treatments that travel through your entire body—is the foundation for preventing the cancer from returning elsewhere. Because ER-positive (ER+) / HER2-negative breast cancer relies on estrogen to grow, the main goal of systemic treatment is to starve the cancer cells of this “fuel” or block them from using it [1].

Endocrine Therapy: The Foundation

Endocrine therapy (often called hormone therapy) is not the same as Hormone Replacement Therapy (HRT). HRT adds hormones to the body, while endocrine therapy blocks them. There are two primary types of daily pills used for 5 to 10 years [2][3]:

Tamoxifen

  • How it works: Tamoxifen is a Selective Estrogen-Receptor Modulator (SERM). It acts like a “broken key” that fits into the estrogen receptor docking station on cancer cells. Once tamoxifen is docked, the real estrogen cannot get in to give the signal to grow [1].
  • Who it’s for: Tamoxifen can be used by both premenopausal and postmenopausal women [1].
  • Side effects: Common side effects include hot flashes and vaginal discharge. Rare but serious risks include blood clots and a small increase in the risk of uterine cancer. Any unusual vaginal bleeding while on tamoxifen should be reported promptly to your doctor [2][4].

Aromatase Inhibitors (AIs)

  • How it works: AIs (anastrozole, letrozole, and exemestane) stop the body from making estrogen in the first place. In postmenopausal women, most estrogen is made by an enzyme called aromatase in fat and muscle tissue. AIs turn this enzyme off [1].
  • Who it’s for: AIs are mainly used for postmenopausal women. If a premenopausal woman takes an AI, her ovaries will simply work harder to overcome it unless they are “shut down” first [1][5].
  • Side effects: AIs often cause joint and muscle pain (arthralgia) and can lead to bone thinning (osteopenia or osteoporosis) [2][6].

Ovarian Function Suppression (OFS)

For younger, premenopausal women with a higher risk of recurrence (such as those who needed chemotherapy), doctors often recommend “shutting down” the ovaries. This is called Ovarian Function Suppression (OFS). Ovarian suppression is not necessarily permanent, and monthly injections are not the only dosing schedule; fertility and contraception should be discussed with your team [5][7]. (This is generally not relevant to a 55-year-old postmenopausal patient.)

Adding OFS to either tamoxifen or an AI can further reduce the risk of the cancer returning, particularly for younger women or those with larger tumors [7][8]. However, it does induce immediate menopause, which can lead to more intense symptoms like hot flashes, sleep disturbances, and changes in sexual health. Its expected benefit is individualized [9][10].

Targeted Therapy for Early High-Risk Disease

For patients with a particularly high clinical risk of the cancer coming back—such as those with multiple positive lymph nodes—doctors may add a CDK4/6 inhibitor to standard endocrine therapy [11][12]. These drugs block proteins called CDK4 and CDK6, which act as the “gas pedal” for cell division.

  • Abemaciclib (Verzenio): Studied in the monarchE trial, this is taken twice daily for two years. It has been shown to significantly reduce the risk of invasive disease returning in selected high-risk, node-positive patients [11].
  • Ribociclib (Kisqali): Studied in the NATALEE trial, this includes some stage II/node-negative patients and is taken for three years [12][13].

An Oncotype RS of 18 in a T2N0 tumor does not itself establish eligibility for these drugs. Safety monitoring depends on the drug and includes checking for early diarrhea, ECG (heart rhythm) and liver testing, blood-count abnormalities, venous thrombosis, and rare pneumonitis [14][15].

Examples Used Only If Metastatic Disease Develops

If the cancer spreads to other parts of the body (metastatic disease), the treatment strategy shifts to using “biomarker-directed” therapies. This involves testing the tumor or blood (liquid biopsy) for specific genetic mutations that the cancer developed [16][17]. These are not part of an early-stage treatment plan.

Target/Mutation Drug Example Purpose in Advanced Disease
CDK4/6 Inhibitors Palbociclib A targeted therapy used in combination with endocrine therapy to slow advanced growth [18].
PIK3CA Alpelisib For tumors with a mutation in the PI3K pathway, used with endocrine therapy [19].
ESR1 Elacestrant An oral pill for cancers that have become resistant to other hormone therapies via ESR1 mutation [20].
AKT/PTEN Capivasertib Targets the AKT signaling pathway to overcome resistance, combined with fulvestrant [21].

The Importance of Adherence

Unlike chemotherapy, which is given in a clinic, these treatments are mostly pills you take at home. Because they must be taken daily for many years, adherence (taking every dose as prescribed) is the most critical factor in their success [8]. If side effects like joint pain or mood changes make it difficult to stay on your medication, it is vital to talk to your doctor. Often, switching to a different AI or managing symptoms with supportive care can help you complete the full course of treatment safely.

Common questions in this guide

What is endocrine therapy for ER-positive breast cancer?
Endocrine therapy is medication that blocks estrogen signals or lowers the amount of estrogen available to ER-positive breast cancer cells. Tamoxifen blocks the estrogen receptor, while aromatase inhibitors reduce estrogen production. Treatment is often taken daily for 5 to 10 years, depending on the treatment plan.
Is tamoxifen or an aromatase inhibitor better for me?
Tamoxifen can be used before or after menopause, while aromatase inhibitors are mainly used after menopause. A premenopausal patient generally needs ovarian function suppression before an aromatase inhibitor can work as intended. Your age, menopausal status, recurrence risk, health history, and side-effect preferences help guide the choice.
When is ovarian suppression added to hormone therapy?
Ovarian function suppression may be added for some premenopausal patients with a higher risk of recurrence, including some who needed chemotherapy or have larger tumors. It can be combined with tamoxifen or an aromatase inhibitor. It causes immediate menopause symptoms, and the expected benefit should be weighed against side effects and personal goals.
Could I receive a CDK4/6 inhibitor after surgery?
Abemaciclib or ribociclib may be added to endocrine therapy for selected patients with high-risk early ER-positive, HER2-negative breast cancer, such as some people with positive lymph nodes. Eligibility depends on the drug, tumor stage, lymph-node status, and other clinical features. An Oncotype RS of 18 in a T2N0 tumor alone does not establish eligibility.
What side effects and monitoring are important with these treatments?
Tamoxifen may cause hot flashes or vaginal discharge, and unusual vaginal bleeding should be reported promptly. Aromatase inhibitors can cause joint or muscle pain and bone thinning, so your team may recommend bone-density monitoring; ovarian suppression can intensify menopause symptoms. CDK4/6 inhibitors require drug-specific monitoring, including checks for diarrhea, blood-count or liver-test changes, heart-rhythm problems, blood clots, and rare lung inflammation.
How can I stay on endocrine therapy if side effects are difficult?
Do not stop or skip endocrine therapy without discussing it with your care team. Clinicians may be able to manage symptoms, provide supportive care, or switch you to another aromatase inhibitor so you can continue treatment. Taking the medicine as prescribed for the recommended duration is important because adherence affects its benefit.
If ER-positive breast cancer spreads, how can mutation testing affect treatment?
For metastatic disease, doctors may test tumor tissue or blood for changes such as PIK3CA or ESR1 mutations. Results can help select biomarker-directed drugs, such as alpelisib for some PIK3CA-mutated cancers or elacestrant for some ESR1-mutated cancers. These examples are for advanced disease and are not part of every early-stage treatment plan.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my age and health history, do you recommend starting with an aromatase inhibitor or tamoxifen?
  2. 2.If I am premenopausal, what are the specific benefits of adding ovarian function suppression (OFS) to my hormone therapy versus taking tamoxifen alone?
  3. 3.Does my tumor meet the 'high-risk' criteria from the monarchE or NATALEE trials to qualify for a CDK4/6 inhibitor like abemaciclib or ribociclib?
  4. 4.What is your plan for monitoring my bone health while I am on these medications? Do I need a baseline bone density (DEXA) scan?
  5. 5.If my cancer were to progress, how would we test my tumor or blood for mutations like PIK3CA or ESR1 to guide our next treatment choice?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (21)
  1. 1

    Cardiometabolic Effects of Endocrine Treatment of Estrogen Receptor-Positive Early Breast Cancer.

    Cheung YM, Ramchand SK, Yeo B, Grossmann M

    Journal of the Endocrine Society 2019; (3(7)):1283-1301 doi:10.1210/js.2019-00096.

    PMID: 31259291
  2. 2

    Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials.

    Lancet (London, England) 2015; (386(10001)):1341-1352 doi:10.1016/S0140-6736(15)61074-1.

    PMID: 26211827
  3. 3

    Pembrolizumab and chemotherapy in high-risk, early-stage, ER+/HER2- breast cancer: a randomized phase 3 trial.

    Cardoso F, O'Shaughnessy J, Liu Z, et al.

    Nature medicine 2025; (31(2)):442-448 doi:10.1038/s41591-024-03415-7.

    PMID: 39838117
  4. 4

    Aromatase inhibitors alone or sequentially combined with tamoxifen in postmenopausal early breast cancer compared with tamoxifen or placebo - Meta-analyses on efficacy and adverse events based on randomized clinical trials.

    Rydén L, Heibert Arnlind M, Vitols S, et al.

    Breast (Edinburgh, Scotland) 2016; (26()):106-14.

    PMID: 27017249
  5. 5

    Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials.

    The Lancet. Oncology 2022; (23(3)):382-392 doi:10.1016/S1470-2045(21)00758-0.

    PMID: 35123662
  6. 6

    The effects of adjuvant endocrine therapy on bone health in women with breast cancer.

    Ramchand SK, Cheung YM, Yeo B, Grossmann M

    The Journal of endocrinology 2019; (241(3)):R111-R124.

    PMID: 30991355
  7. 7

    Final outcomes of the SOFT and TEXT phase III trials in premenopausal hormone receptor-positive early breast cancer.

    Francis PA, Pagani O, Fleming GF, et al.

    Annals of oncology : official journal of the European Society for Medical Oncology 2026; (37(10)):1367-1385 doi:10.1016/j.annonc.2026.05.704.

    PMID: 42229584
  8. 8

    Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials.

    Regan MM, Francis PA, Pagani O, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2016; (34(19)):2221-31 doi:10.1200/JCO.2015.64.3171.

    PMID: 27044936
  9. 9

    Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials.

    Bernhard J, Luo W, Ribi K, et al.

    The Lancet. Oncology 2015; (16(7)):848-58.

    PMID: 26092816
  10. 10

    Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials.

    Saha P, Regan MM, Pagani O, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2017; (35(27)):3113-3122 doi:10.1200/JCO.2016.72.0946.

    PMID: 28654365
  11. 11

    Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial.

    Johnston SRD, Toi M, O'Shaughnessy J, et al.

    The Lancet. Oncology 2023; (24(1)):77-90 doi:10.1016/S1470-2045(22)00694-5.

    PMID: 36493792
  12. 12

    Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2- early breast cancer.

    Slamon DJ, Fasching PA, Hurvitz S, et al.

    Therapeutic advances in medical oncology 2023; (15()):17588359231178125 doi:10.1177/17588359231178125.

    PMID: 37275963
  13. 13

    Timing and Patterns of Relapse-Related Events Following Adjuvant CDK4/6 Inhibitors Combined With Endocrine Therapy in Patients With HR-Positive, HER2-Negative Early Breast Cancer.

    Chen H, Wu S, Shan Y, et al.

    Cancer medicine 2026; (15(8)):e72224 doi:10.1002/cam4.72224.

    PMID: 42634184
  14. 14

    Comparative analysis of adverse events associated with CDK4/6 inhibitors based on FDA's adverse event reporting system: a case control pharmacovigilance study.

    Lin W, Zeng Y, Weng L, et al.

    BMC pharmacology & toxicology 2024; (25(1)):47 doi:10.1186/s40360-024-00770-6.

    PMID: 39123221
  15. 15

    Ribociclib-induced liver injury: a case report.

    Schaeffer S, Lutz C, Dobbie M, et al.

    Frontiers in oncology 2023; (13()):1256783 doi:10.3389/fonc.2023.1256783.

    PMID: 38107071
  16. 16

    Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Update.

    Burstein HJ, Somerfield MR, Barton DL, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2021; (39(35)):3959-3977 doi:10.1200/JCO.21.01392.

    PMID: 34324367
  17. 17

    Navigating the complexity of PI3K/AKT pathway in HER-2 negative breast cancer: biomarkers and beyond.

    Sirico M, Jacobs F, Molinelli C, et al.

    Critical reviews in oncology/hematology 2024; (200()):104404 doi:10.1016/j.critrevonc.2024.104404.

    PMID: 38815877
  18. 18

    Palbociclib and Letrozole in Advanced Breast Cancer.

    Finn RS, Martin M, Rugo HS, et al.

    The New England journal of medicine 2016; (375(20)):1925-1936 doi:10.1056/NEJMoa1607303.

    PMID: 27959613
  19. 19

    Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.

    André F, Ciruelos E, Rubovszky G, et al.

    The New England journal of medicine 2019; (380(20)):1929-1940 doi:10.1056/NEJMoa1813904.

    PMID: 31091374
  20. 20

    Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial.

    Bidard FC, Kaklamani VG, Neven P, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2022; (40(28)):3246-3256 doi:10.1200/JCO.22.00338.

    PMID: 35584336
  21. 21

    Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer.

    Turner NC, Oliveira M, Howell SJ, et al.

    The New England journal of medicine 2023; (388(22)):2058-2070 doi:10.1056/NEJMoa2214131.

    PMID: 37256976

This page is for informational purposes only and does not constitute medical advice. Your oncology team can tailor endocrine or targeted treatment and side-effect monitoring to your health, menopausal status, and recurrence risk.

Get notified when new evidence is published on estrogen-receptor positive breast cancer.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.